[HTML][HTML] Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled …
D Pushkar, A Vinarov, L Spivak… - … European Journal of …, 2018 - ncbi.nlm.nih.gov
Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
[PDF][PDF] Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled …
D Pushkar, A Vinarov, L Spivak, K Kolontarev… - pdfs.semanticscholar.org
Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
Efficacy and safety of afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: A multicenter, double-blind, placebo-controlled, randomized …
D Pushkar, K Kolontarev, A Vinarov, L Spivak… - … European Journal of …, 2018 - elibrary.ru
Efficacy and safety of afalaza in men with symptomatic benign prostatic hyperplasia at risk of
progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial КОРЗИНА …
progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial КОРЗИНА …
Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized …
D Pushkar, A Vinarov, L Spivak… - … European Journal of …, 2018 - europepmc.org
Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized …
D Pushkar, A Vinarov, L Spivak… - … Journal of Urology, 2018 - search.proquest.com
Abstract Dec. 27, 2018 Introduction In order to investigate the efficacy and safety of Afalaza
in men with benign prostatic hyperplasia (BPH) at risk of progression, this multicenter …
in men with benign prostatic hyperplasia (BPH) at risk of progression, this multicenter …
[PDF][PDF] Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled …
D Pushkar, A Vinarov, L Spivak, K Kolontarev… - researchgate.net
Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized …
D Pushkar, A Vinarov, L Spivak… - … journal of urology, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction In order to investigate the efficacy and safety of Afalaza in men with benign
prostatic hyperplasia (BPH) at risk of progression, this multicenter, double-blind, placebo …
prostatic hyperplasia (BPH) at risk of progression, this multicenter, double-blind, placebo …
[PDF][PDF] Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled …
D Pushkar, A Vinarov, L Spivak, K Kolontarev… - researchgate.net
Results IPSS mean change was-3.7±3.0 (95% CI-4.3 to-3.2) after 12 months of Afalaza (vs.-
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …
2.9±2.4; 95% CI-3.3 to-2.4 in placebo; р= 0.02). Qmax growth was 2.5±4.3 ml/s (vs. 1.4±3.3 …